Introduction {#s1}
============

When considering an adult axon, its diameter can oscillate depending on organelle transport ([@bib12]), neuronal activity ([@bib9]), deformations generated by movement or degeneration. The mechanisms controlling axonal diameter throughout the neuronal lifetime remain however unclear. The mature axon shaft is supported by a submembraneous actin-spectrin network- the membrane periodic skeleton (MPS)- composed of actin rings regularly spaced by spectrin tetramers approximately every 190 nm ([@bib31]). Although its assembly and function are largely unknown, the MPS may provide mechanical support for the long thin structure of axons ([@bib13]). In the initial MPS model, each ring was hypothesized to be composed of actin filaments capped by the actin-binding protein adducin ([@bib31]). Recently, combining platinum-replica electron and optical super-resolution microscopy, the MPS actin rings were shown to be made of two long, intertwined actin filaments ([@bib27]). According to this novel view, adducin might be responsible to enhance the lateral binding of spectrin to actin. We have previously demonstrated that adducin is required to maintain axon caliber as its absence in vitro leads to actin rings of increased diameter, while in vivo it results in progressive axon enlargement and degeneration ([@bib21]). We have additionally found that in vitro, the radius of axonal actin ring narrows over time ([@bib21]), supporting that the MPS has dynamic properties. Since reduction in axon diameter with time occurs both in WT and α-adducin knock-out (KO) neurons, MPS dynamics is probably regulated by additional actin-binding proteins.

The role of actin in the control of axonal radial tension is emerging ([@bib6]; [@bib8]). NMII is a hexamer composed by two heavy chains, two regulatory light chains (RLC) and two essential light chains (ELC), being a conserved molecule for generating mechanical forces ([@bib28]). The NMII contractile ATPase activity and the assembly of myosin filaments that coordinate force generation is activated by phosphorylation of myosin light chain (MLC) ([@bib28]). Here, we provide evidence that the axonal MPS, similarly to actin rings present in other biological contexts, is an actomyosin-II network that regulates circumferential axonal contractility. Furthermore, we demonstrate that the MPS affects signal propagation velocity, a property with important functional implications.

Results and discussion {#s2}
======================

Modulation of NMII activity regulates the expansion and contraction of axonal diameter {#s2-1}
--------------------------------------------------------------------------------------

The MPS of both WT and α-adducin KO neurons contracts in vitro at a rate of 6--12 nm/day ([@bib21]). Given the general role of NMII in promoting contractility, we tested whether axon thinning in vitro was dependent on NMII activity. For that, NMII-mediated ATP hydrolysis and thereby actomyosin-based motility, were inhibited by blebbistatin ([@bib26]; [Figure 1A](#fig1){ref-type="fig"}). In the presence of the drug, axon thinning of hippocampal neurons from DIV8 to DIV22 was abolished as determined using Stimulated Emission Depletion (STED) microscopy ([Figure 1B,C](#fig1){ref-type="fig"}). This supports that axon thinning in vitro occurs through a NMII-mediated mechanism. Additionally, DIV8 hippocampal neurons treated with blebbistatin had a 1.3-fold increase in axon diameter ([Figure 1D,E](#fig1){ref-type="fig"}). Alternative modes of drug-mediated modulation of myosin activity were tested, including ML-7 ([@bib25]), calyculin A ([@bib18]), and myovin1 ([@bib11]; [@bib19]). The function of NMII is controlled by MLC kinase (MLCK) that phosphorylates the NMII RLCs leading to conformational changes and self-assembly in myosin filaments ([@bib28]; [Figure 1A](#fig1){ref-type="fig"}). ML-7, a selective MLCK inhibitor that decreases pMLC levels in hippocampal neurons ([Figure 1---figure supplement 1A, B](#fig1s1){ref-type="fig"}), led to an increase in axonal diameter similar to that produced by blebbistatin ([Figure 1D,E](#fig1){ref-type="fig"}). As protein phosphatase 1 (PP1) is the major myosin phosphatase responsible for dephosphorylation of NMII ([@bib23]), calyculin A, a potent PP1 inhibitor that results in increased phosphorylation of NMII RLCs and increased myosin contractility, was used ([@bib17]; [Figure 1A](#fig1){ref-type="fig"}). In the presence of calyculin A, sustained activation of NMII resulted in a decrease to 0.8-fold in axonal diameter ([Figure 1D,E](#fig1){ref-type="fig"}), supporting that NMII activity can positively and negatively regulate axonal caliber. Of note, the effect of calyculin A was reverted by blebbistatin ([Figure 1D,E](#fig1){ref-type="fig"}). Myovin-1, a potent inhibitor of the ATPase activity of myosin V that inhibits myosin V-dependent intersynaptic vesicle exchange in hippocampal neurons ([@bib11]), had no effect on the MPS diameter ([Figure 1D,E](#fig1){ref-type="fig"}) suggesting a NMII-specific effect. In further support of the MPS dynamic nature, the effect of blebbistatin was reverted as drug treatment was released from DIV8 to DIV12 ([Figure 1F,G](#fig1){ref-type="fig"}). In summary, we show that axon diameter can be controlled both at the level of NMII activation through phosphorylation, and at the level of its power-stroke activity.

![Modulation of NMII activity regulates axon diameter.\
(**A**) Representation of NMII structure and activity regulation. NMII contains two heavy chains (HC), two RLCs and two ELCs. The head domain includes an actin-binding site and an ATPase motor domain. ELCs and RLCs are bound to NMII head domains. In the absence of RLC phosphorylation, NMII is in a non-competent conformation. Upon RLC phosphorylation by MLCK, NMII unfolds to generate a competent form. NMII is then able to assemble into bipolar filaments, which bind to actin. MLC phosphatase that includes a regulatory subunit -MYPT1- can revert this activation. NMII activity can be modulated by drugs including ML-7, a specific MLCK inhibitor; calyculin A (CalA) an inhibitor of RLC phosphatase, and blebbistatin (Bleb) that inhibits NMII-mediated ATP hydrolysis. (**B**) Axon diameter of DIV8 and DIV22 hippocampal neurons incubated either with vehicle (veh) or 3 μM blebbistatin (Bleb) at DIV3 and DIV8 (1 hr before fixation); n = 6--8 axons/condition and 20--87 rings/axon. (**C**) Representative STED images of βII-spectrin immunostaining using a STAR 635P secondary antibody related to (**B**). (**D**) Axon diameter of DIV8 rat hippocampal neurons incubated with drug modulators of myosin activity: 3 μM blebbistatin (Bleb), 4 μM ML-7, 5 nM calyculin A (CalA), 5 nM calyculin A + 3 μM blebbistation (CalA+Bleb), 4 μM myovin1 (Myo1) and the respective vehicles (veh). Calyculin A was added at DIV8 (25 min before fixation), while the remaining drugs were added at DIV3 and DIV8 1 hr before fixation; n = 8--13 axons/condition and 10--77 rings/axon. (**E**) Representative STED images of βII-spectrin immunostaining using a STAR 635P secondary antibody related to (**D**). (**F**) Axon diameter of DIV8 rat hippocampal neurons incubated with either 3 μM blebbistatin (Bleb) or vehicle (veh) at DIV3 and DIV8 (1 hr before fixation). In cells treated with blebbistatin up to DIV8, drug was replaced by either vehicle (Bleb+veh) or drug treatment was continued (Bleb+Bleb) and axonal diameter was analysed at DIV12; n = 7--10 axons/condition and 12--79 rings/axon. (**G**) Representative STED images of βII-spectrin immunostaining using a STAR 635P secondary antibody related to (**F**). (**H**) Axon diameter of DIV8 rat hippocampal neurons upon shRNA-mediated knockdown of adducin (sh Adducin) or transfection using a control shRNA (CTR) and subsequent incubation with either Bleb or veh; T- transfected; NT- non-transfected; n = 4--13 axons/condition and n = 12--88 rings/axon. (**I**) Representative STED images of βII-spectrin immunostaining using a STAR 635P secondary antibody related to (**H**). (**J**) Axon diameter of DIV8 rat hippocampal neurons upon shRNA-mediated knockdown of different NMII isoforms (NMIIA, NMIIB and NMIIC), RLC or MYPT1; scramble shRNA was used as control (CTR); shRNA resistant constructs (**R**) for each specific shRNA were used to rescue their effect; T- transfected; NT- non-transfected; n = 5--15 axons/condition and 6--103 rings/axon. (**K**) Representative STED images of βII-spectrin immunostaining using a STAR 635P secondary antibody related to (**J**). (**L**) Tilting (effective angle α~eff~) of the actin rings in relation to the axonal axis after incubation with NMII chemical modulators; similar concentrations and incubation times as defined in (**D**); n = 8--14 axons/condition and 14--72 rings/axon and (**M**) after shRNA-mediated downregulation; n = 5--15 axons/condition and 7--70 rings/axon. Tilting was quantified in STED images after βII-spectrin immunostaining. (**N**) MPS periodicity after incubation with myosin-targeting drugs; similar concentrations and incubation times as defined in (**D**). The average distance between peaks was quantified by STED after βII-spectrin immunostaining; n = 8--14 axons/condition and 14--72 rings/axon. (**O**) MPS periodicity after shRNA-mediated knockdown of different NMII isoforms (NMIIA, NMIIB and NMIIC), RLC or MYPT1; a scramble shRNA was used as control (CTR). The average distance between peaks was quantified by STED after βII-spectrin immunostaining; T- transfected; NT- non-transfected; n = 5--15 axons/condition and 7--70 rings/axon. In all panels: Scale bars, 200 nm. \*p\<0.05; \*\*p\<0.01; \*\*\*\<0.001; \*\*\*\*p\<0.0001; ns-non significant. Graphs show mean ± s.e.m. In every case displayed in this Figure, at least 3 independent experiments have been performed.](elife-55471-fig1){#fig1}

We next asked whether reducing both adducin levels and NMII activity might have a cumulative effect. To test this hypothesis, the MPS was examined in blebbistatin-treated hippocampal neurons where adducin was knocked-down ([Figure 1H,I](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1C, D](#fig1s1){ref-type="fig"}). Whereas inhibiting NMII activity or knocking down adducin led to a 1.3-fold increase in axonal caliber, being the latter case in agreement with our previous studies in adducin KO neurons ([@bib21]), the combination of both treatments did not result in a cumulative effect ([Figure 1H,I](#fig1){ref-type="fig"}).

In mammalian cells, different genes encode three different NMII heavy chain isoforms, NMHCIIA, NMHCIIB and NMHCIIC that determine the NMII isoform (NMIIA, NMIIB and NMIIC, respectively) ([@bib28]). Different NMII isoforms have unique kinetic properties and specific cellular functions ([@bib28]). To understand the role of different NMII isoforms in the MPS, we induced their down-regulation using specific shRNAs ([Figure 1J,K](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1C-L](#fig1s1){ref-type="fig"}). Downregulation of either NMIIA or NMIIB induced a 1.3-fold increase in axon caliber, similar to that induced by either blebbistatin or ML-7 treatment, whereas downregulation of NMIIC was without effect ([Figure 1J,K](#fig1){ref-type="fig"}). These results are in agreement with previous studies highlighting the distinctive mechanochemical profile of NMIIC and lower ability in generating contractile force when compared with NMIIA and NMIIB isoforms ([@bib4]). As such, knockdown of either NMIIA or NMIIB was sufficient to induce a comparable outcome as drug-mediated inhibition of all NMII isoforms, whereas NMIIC probably does not participate in NMII-mediated regulation of axon diameter. shRNA-mediated knockdown of NMII RLC ([@bib29]) had a similar effect to the knockdown of myosin heavy chains, leading to MPS expansion ([Figure 1J,K](#fig1){ref-type="fig"}). Myosin phosphatase target subunit 1 (MYPT1) is the regulatory subunit of myosin light chain phosphatase and is responsible for the dephosphorylation of MLC. The inactivation of its enzymatic activity increases NMII phosphorylation and consequently its activation ([@bib28]; [Figure 1A](#fig1){ref-type="fig"}). Knocking down MYPT1 ([Figure 1](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1E, F, K, L](#fig1s1){ref-type="fig"}) caused a decrease to 0.8-fold in axon diameter ([Figure 1J,K](#fig1){ref-type="fig"}). Of note, rescue experiments performed using co-transfection with shRNA-resistant constructs reverted the phenotype of the corresponding shRNA, confirming their specificity ([Figure 1J,K](#fig1){ref-type="fig"}). Our data support that both NMIIA and NMIIB, contribute to the MPS actomyosin network.

The possible tilting of actin rings in relation to the axonal axis was measured in all the conditions where drug- or shRNA-mediated modulation of NMII activity was performed. No variations in the angle of actin rings in relation to the axonal axis were found ([Figure 1L,M](#fig1){ref-type="fig"}) suggesting that NMII probably does not contract between adjacent rings. Of note, tilting may be hindered by the existence of the βII-spectrin scaffold. Also, having several active NMII filaments attached to adjacent axon rings, may generate a net force that would be averaged out and thus close to zero. Importantly, neither drug- nor shRNA-mediated modulation of NMII activity, resulted in alterations of MPS periodicity ([Figure 1N,O](#fig1){ref-type="fig"}, respectively), thus arguing that a possible participation of NMII in axonal longitudinal tension does not interfere with the 190 nm length of extended spectrin tetramers ([@bib5]).

Propagation velocity is altered by manipulation of NMII activity {#s2-2}
----------------------------------------------------------------

Neuronal electrophysiology is intimately related to morphology. Besides the relation between conduction velocity and axonal caliber ([@bib16]; [@bib30]), sodium channels are distributed in axons in a periodic pattern coordinated with the MPS ([@bib31]). To uncover possible electrophysiological implications of manipulating NMII activity, we used a combination of in vitro microelectrode arrays (MEA) and microfluidics (μEF platforms) to characterize axonal propagation velocity between DIV11 and DIV14. This μEF platform was previously shown by us to allow axon alignment on top of a sequence of microelectrodes, providing detailed electrophysiological information about signal conduction on isolated axons ([Figure 2A](#fig2){ref-type="fig"}) while also recording global activity levels ([@bib15]; [@bib22]). Blebbistatin-treated and untreated neurons were electrophysiologically competent regarding signal conduction and no significant differences in global electrical activity were found, as determined by assessing their mean firing rate (MFR) ([Figure 2B,C](#fig2){ref-type="fig"}). However, axonal conduction velocity between treated and untreated axons was different, with distinct velocity distributions ([Figure 2D,E](#fig2){ref-type="fig"}). From DIV11 on, blebbistatin-treated neurons consistently showed higher propagation velocities when compared to vehicle-treated cells. In unmyelinated axons, velocity conduction is proportional to the square root of the axonal diameter ([@bib16]) and blebbistatin treatment produces a 1.3-fold increase in axon diameter that is not altered throughout time ([Figure 1F](#fig1){ref-type="fig"}). Our data favors that NMII modulation affects axonal electrophysiology through changes in axonal diameter. This effect should be further explored by using additional modulators of NMII activity and shRNA-mediated downregulation approaches.

![Blebbistatin treatment increases axonal signal propagation velocity.\
(**A**) Single propagating event recorded along four electrodes inside a microchannel. Each colored signal trace corresponds to an electrode from a single microchannel. Two microchannels are indicated by asterisks in the phase-contrast image of hippocampal neurons cultured on a μEF platform at DIV8 (scale bar = 50 μm). (**B**) Activity maps of vehicle and 3 μM blebbistatin (Bleb) treated cultures at DIV11. Each pixel corresponds to one recording electrode and the mean firing rate (MFR) is color-coded for each electrode. Notice that μEFs allow for the recording of both somal and axonal activity. Below are shown raster plots of 300 s of activity from 16 active electrodes of the somal compartment and from 16 electrodes within the microchannels (one electrode per microchannel). (**C**) MFR from the electrodes in the microchannels for vehicle and Bleb-treated cultures (DIV11-14). (**D**) Median propagation velocity (± SD) for vehicle and blebbistatin-treated cultures at DIV11, 12, and 14 (propagating events pooled from 25 to 43 microchannels, from 3 to 4 independent μEFs). Unpaired t-test or Mann-Whitney test; ns = not significant, \*\*p\<0.01, \*\*\*p\<0.001 and \*\*\*\*p\<0.0001. (**E**) Frequency distribution of the propagation velocity domains (0.05 m/s binning) at DIV11 for both conditions.](elife-55471-fig2){#fig2}

Phosphorylated NMII light chains are colocalized with actin within the MPS and organized as circular periodic structures persisting throughout the axon shaft {#s2-3}
-------------------------------------------------------------------------------------------------------------------------------------------------------------

We next analyzed the localization of NMII in axons using STED microscopy, and 3D Single Molecule Localization Microscopy (SMLM) with a dSTORM/GSDIM-protocol ([@bib10]; [@bib14]). pMLC has been described to be specifically localized in the axon initial segment (AIS) ([@bib3]). pMLC regulates the head groups of the NMII heavy chains, mediating their binding to actin and the organization of NMII into bipolar filaments ([@bib3]). Despite the enrichment of pMLC at the AIS, not only non-phosphorylated MLC, but also active pMLC could be observed throughout the entire axon shaft ([Figure 3A](#fig3){ref-type="fig"}). By applying SMLM to the AIS of DIV8 hippocampal neurons and focusing on their lateral outermost points up to the axonal surface, pMLC displayed a bilateral \~200 nm periodicity and a circular structure ([Figure 3B,C](#fig3){ref-type="fig"}; [Video 1](#video1){ref-type="video"}). Periodic (\~190 nm) pMLC staining, coincident with phalloidin staining restricted to the AIS, has been previously shown using STORM ([@bib3]), suggesting a direct binding of pMLC to actin. Here, we show that pMLC periodicity is not restricted to the AIS, extending to the axon shaft, being visible in the lateral outer part of the axon ([Figure 3D](#fig3){ref-type="fig"}- highlighted by white ruler; and ***3E***). Interestingly, in some axonal regions, pMLC showed a periodic distribution, consistent with anchoring in different positions of adjacent actin rings ([Figure 3D](#fig3){ref-type="fig"}- highlighted by red ruler; and [Figure 3F](#fig3){ref-type="fig"}). The absence of a generalized striped pattern for pMLC (in contrast to what is observed for axonal actin and βII-spectrin staining), supports that in each actin ring a limited number of pMLC molecules is anchored. Alternatively, technical limitations of the antibodies used may preclude the visualization of the entire pool of pMLC molecules present in the structure. However, in some regions of the axon shaft of hippocampal neurons, pMLC not only displays the expected striped pattern but also is colocalized with actin, supporting that throughout the axon, pMLC is bound to actin rings that compose the MPS ([Figure 3G](#fig3){ref-type="fig"}). Simultaneous analysis of βII-spectrin and pMLC using dual color SMLM showed that in the axon shaft the two molecules intercalate ([Figure 3H](#fig3){ref-type="fig"}, arrowheads highlight pMLC and asterisks βII-spectrin), whereas a periodic distribution of pMLC consistent with anchoring in different positions of adjacent actin rings also occurs, in both cases non-overlapping with βII spectrin ([Figure 3H](#fig3){ref-type="fig"}).

![Phosphorylated NMII light chains are organized as circular periodic structures persisting throughout the axon shaft.\
(**A**) Immunolabeling of DIV8 hippocampal neurons with rabbit anti-pMLC (left) and rabbit anti-total MLC (right) using a secondary anti- rabbit Alexa Fluor 647 antibody. Scale bar: 5 μm. (**B**) Single colour SMLM of pMLC distribution in the AIS using a secondary Alexa Fluor 647 antibody. Scale bar: 500 nm. (**C**) Analysis of the periodicity related to (**B**). (**D**) 2D single colour SMLM of the axon shaft of a DIV8 hippocampal neuron immunostained for pMLC using a secondary Alexa Fluor 647 antibody. Scale bar: 500 nm. Periodic distribution in outer most regions of the axon shaft is highlighted with white ruler; inner distribution consistent with anchoring in different positions of adjacent actin rings is highlighted with red ruler. (**E**) Analysis of periodicity in outer most regions of the axon shaft (highlighted in white in D). (**F**) Analysis of inner periodic distribution (highlighted in red in D). (**G**) Two colour STED of a DIV8 hippocampal neuron immunostained against pMLC (red) and stained for actin (gray), using a STAR 580 secondary antibody and phalloidin 635, respectively. pMLC molecules, highlighted with arrowheads, co-localize with actin. Scale bar: 200 nm. The raw image was deconvolved using the CMLE algorithm (Huygens Professional, Scientific Volume Imaging). (**H**) Z projection of 3D two-colour SMLM of a DIV8 hippocampal neuron immunostained against βII-spectrin (red) and pMLC (green) using secondary antibodies labeled with Alexa Fluor 532 and 647, respectively. Molecules intercalating at outermost positions are highlighted using arrowheads (pMLC) and asterisks (βII-spectrin). Scale bar: 500 nm.](elife-55471-fig3){#fig3}

###### 3D single colour SMLM of pMLC distribution in the AIS of a DIV8 hippocampal neuron.

Scale bar: 500 nm.

NMII heavy chains are present along the longitudinal axonal axis, being able to crosslink adjacent rings {#s2-4}
--------------------------------------------------------------------------------------------------------

To characterize the spatial location of NMII heavy chains, we used antibodies that recognize the C-terminal tail region of NMIIA and NMIIB heavy chains, which label the middle portion of NMII bipolar filaments ([Figure 4A](#fig4){ref-type="fig"}). Using these antibodies, we started by performing two-color STED in combination with phalloidin staining. When focusing the axonal lateral outermost points, both NMII heavy chain A ([Figure 4B](#fig4){ref-type="fig"}) and NMII heavy chain B ([Figure 4C](#fig4){ref-type="fig"}) were mainly detected within the axon core. At discrete sites, NMIIA and NMIIB colocalized with phalloidin ([Figure 4B,C](#fig4){ref-type="fig"}- highlighted with arrowheads), suggesting that NMII heavy chains might additionally be within individual actin rings. Although no simultaneous labeling of NMIIA and NMIIB was performed given host antibody constraints, their localization within axons did not differ significantly ([Figure 4B,C](#fig4){ref-type="fig"}). When observing axons single-labeled for NMIIA using SMLM, a pattern emerged suggesting the existence of multiple NMIIA heavy chain filaments along the longitudinal axonal axis ([Figure 4D](#fig4){ref-type="fig"}). Of note, this organization clearly contrasted with the circular periodic distribution of pMLC ([Figure 3B](#fig3){ref-type="fig"}; [Video 1](#video1){ref-type="video"}).

![NMII heavy chains organize into filaments distributed in multiple orientations along the axon shaft.\
(**A**) Representation of recognition sites of antibodies against NMIIA and NMIIB (NMIIA: 1949--1960 aa; NMIIB: 1965--1976 aa). (**B**) Representative STED analysis of a DIV8 hippocampal neuron co-stained with NMIIA using a secondary anti-rabbit STAR 580 (upper) and phalloidin 635 (middle); the merged image is shown in the lower panel. Scale bar: 200 nm. (**C**) Representative STED analysis of a DIV8 hippocampal neuron co-stained with NMIIB using a secondary anti-rabbit STAR 580 (upper) and phalloidin 635 (middle); the merged image is shown in the lower panel. Scale bar: 200 nm. (**D**) Z projection of 3D SMLM of an axon single labeled for NMII heavy chain A using an Alexa Fluor 647 labeled secondary antibody. NMIIA labeling following different orientations in relation to the axonal axis is highlighted with arrowheads. Scale bar: 500 nm. (**E**) Representation of a bipolar NMIIA filament, with the N-terminal eGFP tagged and the C-terminal mApple tagged. (**F**) SH-SY5Y was immunolabelled with βII-spectrin using a STAR 635P secondary and imaged using STED. Scale bar: 200 nm. The raw image was deconvolved using the CMLE algorithm (Huygens Professional, SVI). (**G**) Analysis of SH-SY5Y βII-spectrin periodicity related to (**F**). (**H**) Representative spinning disk image of SH-SY5Y after co-transfection with eGFP-NMIIA and NMIIA-mApple. Scale bar: 1 µm. Insets highlight bipolar NMIIA filaments of \~300 nm. (**I**) Representative spinning disk image of a primary hippocampal neuron axon after co-transfection with eGFP-NMIIA and NMIIA-mApple. Scale bar: 1 µm. (**J**) Z projection of a 3D SMLM double stained for βII-spectrin (red) and NMII heavy chain A (green) using anti-mouse Alexa Fluor 532 and anti-rabbit Alexa Fluor 647, respectively. Scale bar: 500 nm. (**K**) Analysis of the envelope of NMIIA labeling (Z projection) relative to the region highlighted by the white box in (**J**); the axonal membrane (dashed line) and centerline (solid line) are depicted. Scale bar: 1 µm. (**L**) Computer 3D reconstruction of the SMLM double stained for βII-spectrin (red) and NMII heavy chain A (green) of the image shown in (**J**). Solid line follows the axon centerline, whereas the dashed line marks the cellular membrane. The red scale bar is 1.7 µm, which corresponds to the size of the βII-spectrin secondary structure (see panel O). A Z projection is shown. (**M**) Y projection related to (**J**). (**N**) Co-localization of βII-spectrin and NMII heavy chain A for the reconstruction shown in (**L**). (**Q**) Fluorescence intensity spatial frequency of βII-spectrin on the axonal axis, analyzed by Fourier transform. In addition to the 0.20 µm peak (marked with '\#"), there is also a consistent peak at 1.7 µm (marked with '\*"). (**P**) Models for the distribution of the NMII along axons. NMII filaments may crosslink adjacent actin rings (model a) or span individual rings (model b), in both cases with variable angles relative to the axonal axis.](elife-55471-fig4){#fig4}

To further assess the localization of NMII heavy chains in axons, the SH-SY5Y neuroblastoma cell line and primary hippocampal neurons were transfected with fluorescent NMII fusion constructs that allow visualizing simultaneously the N-terminal (eGFP tag) and C-terminal (mApple tag) domains of the NMIIA heavy chain ([@bib2]; [Figure 4E](#fig4){ref-type="fig"}). Of note, in differentiated SH-SY5Y cells, the approximately 190 nm MPS periodic pattern of βII-spectrin was observed ([Figure 4F,G](#fig4){ref-type="fig"}). We used super-resolution spinning disk microscopy to study differentiated SH-SY5Y ([Figure 4H](#fig4){ref-type="fig"}) and primary hippocampal neurons ([Figure 4I](#fig4){ref-type="fig"}). We show that in axons of both cell types, NMIIA can assemble into bipolar filaments of \~300 nm in length, consisting of eGFP puncta at the ends of the filament (N-terminus of head domains) with a single mApple punctum (C-terminus of tail domains) in the middle ([Figure 4H,I](#fig4){ref-type="fig"}). Similarly to the data obtained by STORM ([Figure 4D](#fig4){ref-type="fig"}), fluorescent NMII fusion proteins revealed the existence of multiple consecutive myosin filaments positioned along the axonal axis ([Figure 4H,I](#fig4){ref-type="fig"}).

Dual color SMLM for the simultaneous analysis of βII-spectrin and NMIIA, further suggested that NMII heavy chain A is mainly positioned within the axon core forming several filaments with different orientations in relation to the axon shaft ([Figure 4J](#fig4){ref-type="fig"}; [Video 2](#video2){ref-type="video"}). The analysis of the NMIIA labeling envelope, that is, the smooth curve outlining the extremes of NMIIA labeling, showed variable orientations with respect to the axonal longitudinal axis ([Figure 4K](#fig4){ref-type="fig"}). This supports that NMIIA filaments are not strictly aligned with the axonal axis. 3D reconstructions were performed to quantify spatial properties ([Figure 4L--N](#fig4){ref-type="fig"}). SMLM showed sites of colocalization of NMIIA heavy chain and βII-spectrin ([Figure 4N](#fig4){ref-type="fig"}), which suggests the existence of NMII filaments crosslinking adjacent rings ([Figure 4Q](#fig4){ref-type="fig"}, model a). Recently, immunogold labeling of pMLC followed by platinum-replica electron microscopy showed gold beads along filaments perpendicular to actin rings ([@bib27]). This led to the hypothesis that these filaments might correspond to myosins associated with the MPS, cross-linking neighboring rings, which goes along our observations. One should however note that in our analysis, some of the NMIIA staining was non-coincident with βII-spectrin, thus pointing towards a possible NMIIA filament distribution within actin rings ([Figure 4Q](#fig4){ref-type="fig"}, model b). As expected, βII-spectrin showed a prominent peak in the spatial frequency domain, corresponding to a 197 nm periodicity ([Figure 4O](#fig4){ref-type="fig"}, highlighted with \#). Interestingly, a second pronounced peak at 1.71 µm was also observed ([Figure 4O](#fig4){ref-type="fig"}, highlighted with \*), suggesting a possible secondary structure arrangement of βII-spectrin in axons, that should be the subject of further analysis.

###### 3D two-color SMLM of DIV8 hippocampal neurons immunostained against βII-spectrin (red) and NMIIA (green).

Scale bar: 500 nm.

Structural organization and dynamics of actomyosin axonal rings {#s2-5}
---------------------------------------------------------------

Our findings highlight possible distinct spatial positions of NMII filaments with respect to the MPS, which correlate with different biomechanical roles. NMII filaments crosslinking adjacent actin rings ([Figure 4P](#fig4){ref-type="fig"}, model a) are not expected to provide for radial contractility but provide for scaffolding. NMII filaments within individual actin rings ([Figure 4P](#fig4){ref-type="fig"}, model b), represent the conformation capable of generating the highest contractile force leading to actin filament sliding along the ring. Assuming that the MPS actin rings are composed of two parallel, intertwined actin filaments ([@bib27]), NMII activity could provide for contraction by putting the two actin filaments in registry with each other. One should however note that from the images presented ([@bib27]), a non-uniform distribution of NMII along the actin structures is observed which, to our understanding, cannot generate significant contractile force but rather hold a crosslinking function.

It is possible that in a single ring, NMII filaments with scaffolding and contractile roles might co-exist. Additionally, scaffolding and contractile roles may switch via change in activity of the NMII motors. Pharmacological NMII inhibition may lead to ring expansion given loss of both scaffolding and contractile roles; as a consequence, the inner axonal tension will lead to increased axon diameter. When axonal diameter is restored, contractile NMII filaments may perform ring contraction, favored by transient absence of scaffolding filaments. Eventually, scaffolding NMII may be restored and contraction may slow down to its original low rate. In physiological responses (such as axon diameter increase upon cargo trafficking) at an initial stage, scaffolding NMII may be reduced to a minimum, while contractile filaments cannot prevent ring expansion. At a second stage (when cargo moves), contractile NMII may lead to a fast return to the original diameter. Eventually, scaffolding filaments may be restored and the contraction rate will return to a very low value. One should however bear in mind that despite the fact that NMII activity modulates MPS diameter, and that pMLC colocalizes with MPS actin both in the AIS and in the axon shaft, the interplay between NMII and deep axonal actin filaments may also occur. In this scenario, the possibility that these alternative axonal actin arrangements may also serve as myosin anchors cannot be ruled out and should be certainly explored in the future. In summary, our data supports that NMII regulates circumferential axonal contraction and expansion. These findings have important implications on our understanding of neuronal biology, including fluctuations in axonal diameter observed during trafficking, action potential firing and axon degeneration.

Materials and methods {#s3}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\             Designation                                                    Source or\                              Identifiers                                                                         Additional\
  (species) or\                                                                            reference                                                                                                                   information
  resource                                                                                                                                                                                                             
  ------------------------- -------------------------------------------------------------- --------------------------------------- ----------------------------------------------------------------------------------- ------------------------------
  Antibody                  Rabbit polyclonal anti-NMIIA                                   Sigma-Aldrich                           Cat\# M8064, RRID:[AB_260673](https://scicrunch.org/resolver/AB_260673)             WB_1:1000; IF_1:200

  Antibody                  Rabbit polyclonal anti-NMIIB                                   Sigma-Aldrich                           Cat\# M7939, RRID:[AB_260669](https://scicrunch.org/resolver/AB_260669)             WB_1:1000; IF_1:200

  Antibody                  Rabbit polyclonal canti-α-adducin                              Abcam                                   Cat\# ab51130,\                                                                     WB_1:1000
                                                                                                                                   RRID:[AB_867519](https://scicrunch.org/resolver/AB_867519)                          

  Antibody                  Rabbit monoclonal anti-vinculin                                Abcam                                   Cat\# ab129002, RRID:[AB_11144129](https://scicrunch.org/resolver/AB_11144129)      WB_1:1000

  Antibody                  Mouse monoclonal anti-βactin                                   Sigma-Aldrich                           Cat\# A5441, RRID:[AB_476744](https://scicrunch.org/resolver/AB_476744)             WB_1:5000

  Antibody                  Mouse monoclonal anti-αtubulin                                 Sigma-Aldrich                           Cat\# T6199, RRID:[AB_477583](https://scicrunch.org/resolver/AB_477583)             WB_1:1000

  Antibody                  Peroxidase-AffiniPure donkey polyclonal\                       Jackson Immuno Research Labs            Cat\# 711-035-152, RRID:[AB_10015282](https://scicrunch.org/resolver/AB_10015282)   WB_1:5000
                            anti-rabbit IgG (H+L)                                                                                                                                                                      

  Antibody                  Peroxidase-AffiniPure donkey polyclonal anti-mouse IgG (H+L)   Jackson Immuno Research Labs            Cat\# 715-035-151, RRID:[AB_2340771](https://scicrunch.org/resolver/AB_2340771)     WB_1:5000

  Antibody                  Mouse monoclonal anti-βII-spectrin                             BD Transduction                         Cat\# 612563,RRID:[AB_399854](https://scicrunch.org/resolver/AB_399854)             IF_1:200

  Antibody                  Rabbit polyclonal anti-MAP2                                    Synaptic Systems                        Cat\# 188002, RRID:[AB_2138183](https://scicrunch.org/resolver/AB_2138183)          IF_1:20000

  Antibody                  Rabbit polyclonal anti-NMIIC                                   Robert Adelstein NHLBI, Bethesda, USA   N/A                                                                                 IF_1:40

  Antibody                  Rabbit polyclonal anti-pMLC2 Thr18/Ser19                       Cell Signaling                          Cat\# 3674, RRID:[AB_2147464](https://scicrunch.org/resolver/AB_2147464)            IF_1:50

  Antibody                  Rabbit polyclonal anti-MYPT1                                   Cell Signaling                          Cat\# 2634, RRID:[AB_915965](https://scicrunch.org/resolver/AB_915965)              IF_1:50

  Antibody                  Rabbit monoclonal anti-MLC2                                    Cell Signaling                          Cat\# 1678505S                                                                      IF_1:40

  Antibody                  Goat polyclonal anti-mouse STAR 635P                           Abberior GmbH                           Cat\# 2-0002-007-5                                                                  IF_1:200

  Antibody                  Goat polyclonal anti-rabbit STAR 635P                          Abberior GmbH                           Cat\# 2-0012-007-2                                                                  IF_1:200

  Antibody                  Goat polyclonal anti-mouse STAR 580                            Abberior GmbH                           Cat\# 2-0002-005-1, RRID:[AB_2620153](https://scicrunch.org/resolver/AB_2620153)    IF_1:200

  Antibody                  Goat polyclonal anti-mouse STAR 580                            Abberior GmbH                           Cat\# 2-0012-005-8                                                                  IF_1:200

  Antibody                  Goat polyclonal anti- mouse Alexa Fluor 532                    Thermo Fischer Scientific               Cat\# A-11002, RRID:[AB_2534070](https://scicrunch.org/resolver/AB_2534070)         IF_1:200

  Antibody                  Donkey polyclonal anti- rabbit Alexa Fluor 647                 Jackson ImmunoResearch                  Cat\# 711-605-152                                                                   IF_1:1000 STORM\_ 1:200

  Chemical compound, drug   Blebbistatin                                                   Sigma-Aldrich                           Cat\# B0560                                                                         3 µM

  Chemical compound, drug   ML-7                                                           Sigma-Aldrich                           Cat\# I2764                                                                         4 µM

  Chemical compound, drug   Myovin1                                                        Calbiochem                              Cat\# 475984                                                                        4 µM

  Chemical compound, drug   Calyculin A                                                    Sigma-Aldrich                           Cat\# C5552                                                                         5 nM

  Chemical compound, drug   Dimethyl sulfoxide (DMSO)                                      VWR International                       Cat\# A3672.0050                                                                    N/A

  Chemical compound, drug   Phalloidin 635P                                                Abberior GmbH                           Cat\# 2-0205-002-5                                                                  0.33 µM

  Cell line                 CAD (mouse)                                                    ECACC through\                          Cat\# 08100805, RRID:[CVCL_0199](https://scicrunch.org/resolver/CVCL_0199)          N/A
                                                                                           Sigma-Aldrich                                                                                                               

  Cell line                 PC-12 (rat)                                                    ATCC                                    Cat\# CTL-1721, RRID:[CVCL_F659](https://scicrunch.org/resolver/CVCL_F659)          N/A

  Cell line                 SH-SY5Y (human)                                                ATCC                                    Cat\# CRL-2266, RRID:[CVCL_0019](https://scicrunch.org/resolver/CVCL_0019)          N/A

  Recombinant DNA reagent   pEGFP-C1                                                       Addgene                                 N/A                                                                                 N/A

  Recombinant DNA reagent   pLKO.1                                                         Addgene                                 N/A                                                                                 N/A

  Recombinant DNA reagent   shRNA NMIIA                                                    [@bib24]                                N/A                                                                                 5'GCGATACTACTCAGGGCTTAT3'

  Recombinant DNA reagent   shRNA NMIIB                                                    This paper                              N/A                                                                                 5'GCCAACATTGAAACATACCT3'

  Recombinant DNA reagent   shRNA NMIIC                                                    This paper                              N/A                                                                                 5'CCGGGCTCATTTATACCTACT3'

  Recombinant DNA reagent   shRNA RLC                                                      [@bib29]                                N/A                                                                                 5′GCACGGAGCGAAAGACAAA3′

  Recombinant DNA reagent   shRNA MYPT1                                                    This paper                              N/A                                                                                 5′GAGCCTTGATCAGAGTTATAAC3′

  Recombinant DNA reagent   shRNA α-adducin                                                Sigma-Aldrich                           Cat\# TRCN0000108809                                                                5'GCAGAAGAAGAGGGTGTCTAT3'

  Recombinant DNA reagent   Human mutated ShRNA-resistant NMIIA                            This paper                              N/A                                                                                 Vectorbuilder\
                                                                                                                                                                                                                       Page 20_line 374--376

  Recombinant DNA reagent   Human mutated ShRNA-resistant NMIIB                            This paper                              N/A                                                                                 Vectorbuilder\
                                                                                                                                                                                                                       Page 20_line 374--376

  Recombinant DNA reagent   Human ShRNA-resistant RLC                                      Addgene                                 Cat \#35680                                                                         N/A

  Recombinant DNA reagent   Human mutated ShRNA-resistant MYPT1                            This paper                              N/A                                                                                 Vectorbuilder\
                                                                                                                                                                                                                       Page 20_line 374--376

  Recombinant DNA reagent   CMV-eGFP-NMIIA                                                 Addgene                                 Cat \#11347                                                                         N/A

  Recombinant DNA reagent   CMV-NMIIA-mApple                                               John Hammer, NHLBI, Bethesda, USA       N/A                                                                                 N/A

  Commercial assay or kit   NZY Total RNA Isolation Kit                                    NZY Tech                                Cat\# MB13402                                                                       N/A

  Commercial assay or kit   SuperScript First-Strand Synthesis System for RT-PCR           Thermo Fisher Scientific                Cat\# 11904018                                                                      N/A

  Sequence-based reagent    NMIIC sense primer                                             This paper                              N/A                                                                                 5'CCTGGCTGAGTTCTCCTCAC3'

  Sequence-based reagent    NMIIC antisense primer                                         This paper                              N/A                                                                                 5'TGCTTCTGCTCCATCATCTG3'

  Sequence-based reagent    RLC sense primer                                               This paper                              N/A                                                                                 5'CCTTTGCCTGCTTTGATGAG3'

  Sequence-based reagent    RLC antisense primer                                           This paper                              N/A                                                                                 5'GTGACTGGGATGGGGTGTAG3'

  Sequence-based reagent    MYPT1 sense primer                                             This paper                              N/A                                                                                 5'AAGGGAACGAAGAGCTCTAGAAA3\'

  Sequence-based reagent    MYPT1 antisense primer                                         This paper                              N/A                                                                                 5'TGACAGTCTCCAGGGGTTCT3'

  Sequence-based reagent    β-actin sense primer                                           This paper                              N/A                                                                                 5'ACCACACCTTCTACAATGAG3'

  Sequence-based\           β-actin antisense primer                                       This paper                              N/A                                                                                 5'TAGCACAGCCTGGATAGC3'
  reagent                                                                                                                                                                                                              

  Sequence-based reagent    GADPH sense primer                                             This paper                              N/A                                                                                 5'AGGCACCAAGATACTTACAAAAAC3'

  Sequence-based reagent    GADPH antisense primer                                         This paper                              N/A                                                                                 5'TGTATTGTAACCAGTCATCAGCA3\'

  Software, algorithm       MATLAB R2018a                                                  MATLAB                                  RRID:[SCR_001622](https://scicrunch.org/resolver/SCR_001622)                        N/A

  Software,\                Fiji                                                           NIH                                     SRRID:[SCR_002285](https://scicrunch.org/resolver/SCR_002285)                       N/A
  algorithm                                                                                                                                                                                                            

  Software, algorithm       Leica LAS X software                                           Leica                                   RRID:[SCR_013673](https://scicrunch.org/resolver/SCR_013673)                        N/A

  Software, algorithm       µSpikeHunter software                                          [@bib15]                                N/A                                                                                 N/A

  Software, algorithm       GraphPad Prism                                                 GraphPad                                RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)                        N/A

  Software, algorithm       Huygens Software                                               Scientific Volume Imaging               RRID:[SCR_014237](https://scicrunch.org/resolver/SCR_014237)                        N/A
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Hippocampal neuron cultures {#s3-1}
---------------------------

Mice and rat hippocampal neuron cultures were performed as described previously ([@bib20]). Briefly, the hippocampus of each individual E18 embryo was digested 15 min in 0.06% trypsin from porcine pancreas solution (Sigma-Aldrich, cat\# T4799) and triturated. Either 12,500 cells/coverslip (for STED imaging) or 50,000 cells/coverslip (for SMLM imaging) were plated onto 50 µg/mL poly-L-lysine hydrobromide (Sigma-Aldrich, cat\# P2636-100MG) pre-coated 1.5H glass 13 mm rounded coverslips (Marienfeld, for STED imaging) or 22 × 22 mm coverslips (Corning, for SMLM imaging) in 24- or 6-well plates (Nunc). Neurons were cultured in Neurobasal medium (Thermo Fisher Scientific, cat\# 21103--049) supplemented with 2% B-27 (Thermo Fisher Scientific, cat\# 0080085SA), 1% penicillin/streptomycin (Thermo Fisher Scientific, cat\# 15140--122) and 2 mM L-glutamine (Thermo Fisher Scientific, cat\# 25030024). In all conditions, cells were fixed with 4% (w/v) paraformaldehyde (PFA) in phosphate-buffered saline (PBS) at pH7.4 for 20 min at room temperature.

Cell lines {#s3-2}
----------

CAD cells (mouse catecholaminergic neuronal cell line¸ ECACC through Sigma-Aldrich cat\# 08100805; authenticated by DNA barcoding; mycoplasma contamination testing status: negative), PC-12 cells (rat adrenal gland pheochromocytoma, ATCC cat\# CTL-1721; mycoplasma contamination testing status: negative) and SH-SY5Y cells (human neuroblastoma, ATCC cat\# CRL-2266; mycoplasma contamination testing status: negative) were used in specific experiments as detailed below. Both CAD and PC-12 cells were maintained in Dulbecco's modified Eagle's medium (DMEM, Sigma-Aldrich, cat\# D6429-500ML) supplemented with 10% fetal bovine serum (FBS, Sigma-Aldrich, cat\#F9665-500ML), and 1% penicillin/streptomycin, while SH-SY5Y cells were cultured in DMEM:F12 (Sigma-Aldrich, cat\# D8437−6 × 500 ML) 1:1, with 10% FBS, and 1% penicillin/streptomycin. SH-SY5Y were differentiated as detailed ([@bib7]). Briefly, 6500 cells were plated on 10 µg/mL poly-D-lysine hydrobromide (Sigma-Aldrich, cat\# P0899) and 5 µg/mL laminin (Sigma-Aldrich, cat\# L2020) pre-coated 1.5H glass 13 mm rounded coverslips (Marienfeld, for STED imaging) in a 24-well plate (Nunc). In the following day, media was supplemented with 10 µM retinoic acid (Sigma-Aldrich, cat\# R2625) and renewed every other day for 5 days. At day 6, the media was changed for DMEM:F12 with 2% B-27, 1% penicillin/streptomycin and brain derived neurotrophic (BDNF, Sigma-Aldrich, cat\# B3795, 50 ng/ml); at day 9 differentiated cells were used for imaging.

Modulation of MNII activity using pharmacological agents {#s3-3}
--------------------------------------------------------

To modulate myosin activity, blebbistatin (Sigma-Aldrich, **cat\#** B0560, 3 µM), ML-7 (Sigma-Aldrich, cat\# I2764, 4 µM), or myovin1 (Calbiochem, cat\# 475984, 4 µM), were added to hippocampal neurons at DIV3 and at DIV8 1 hr prior to fixation. Calyculin A (Sigma-Aldrich, cat\# C5552, 5 nM) was added to hippocampal neurons at DIV8, 25 min prior to fixation. For all drugs, dimethyl sulfoxide (DMSO, VWR International, cat\# A3672.0050) was used as a vehicle. In control conditions, vehicle alone was used at the same concentration as in the respective experimental condition. For the analysis of the effect of blebbistatin in in vitro thinning, the drug or its vehicle were additionally added at DIV16 and at DIV22 1 hr prior to fixation. To evaluate the reversibility of the effect of blebbistatin, at DIV8 the drug was either replaced by vehicle, or fresh drug was added to the culture. To confirm the inhibitory effect of ML-7 on RLC phosphorylation, hippocampal neurons were incubated with either vehicle or ML-7 (4 µM) at DIV8 1 hr prior fixation and immunofluorescence against pMLC was conducted as detailed below. To evaluate reversibility of the effect of calyculin A on axonal diameter, hippocampal neurons were treated with blebbistatin (3 µM) and calyculin A (5 nM) at DIV8; 25 min later the cells were fixed. To evaluate a possible cumulative effect of adducin and NMII in axonal diameter, sh-mediated knockdown of α-adducin was performed at DIV3 (detailed below) and either blebbistatin or vehicle were added at DIV4 and DIV8 1 hr before fixation. shRNA-mediated downregulation shRNA constructs against NMIIA, NMIIB, NMIIC, RLC, MYPT1 and α-adducin were used. Sequences were the following: for NMIIA 5'-GCGATACTACTCAGGGCTTAT-3' ([@bib24]); for NMIIB 5'-GCCAACATTGAAACATACCT-3' (VectorBuilder); for NMIIC 5'-CCGGGCTCATTTATACCTACT-3' (VectorBuilder); for RLC 5′-GCACGGAGCGAAAGACAAA-3′ ([@bib29]); for MYPT1 5′-GAGCCTTGATCAGAGTTATAAC-3′ (Vector Builder) and for α-adducin 5'-GCAGAAGAAGAGGGTGTCTAT-3' (TRCN0000108809, Sigma). In each case, rescue experiments were performed using shRNA-resistant constructs containing 2--3 mismatches in relation to the respective shRNA. For NMIIA, NMIIB and MYPT1 these were designed and ordered from Vector Builder; for RLC, the shRNA-resistant construct was obtained from Addgene (\#35680). In control conditions, the pLKO.1 empty vector (Addgene) or a shRNA scramble plasmid (VectorBuilder) were used. At DIV3 hippocampal neurons were co-transfected with specific shRNAs and pEGFP-C1 (0.5 µg:0.25 µg/wells) or in the case of rescue experiments, additionally with the respective shRNA-resistant construct (0.5 µg/well) using Lipofectamine 3000 (Thermo Fisher Scientific, cat\# L3000001) according to the manufacturer's instructions. Cells were fixed at DIV8. In all conditions, transfected (EGFP-positive) and non-transfected (EGFP-negative) cells in the same well were used for analysis. To validate shRNAs, CAD cells, PC-12 cells and hippocampal neurons were used. CAD and PC-12 cells were seeded at a density of 250000 cells/well while hippocampal neurons at a density of 12500 cells/well in 24-well plates and co-transfected with specific shRNAs and pEGFP-C1 (1.5 µg:0.5 µg) using Lipofectamine 2000 (Thermo Fisher Scientific, cat\# 116678030) for cell lines, and Lipofectamine 3000 for hippocampal neurons. To evaluate shRNA efficiency, either Western blot analysis of CAD or PC-12 cells (for adducin, NMIIA and NMIIB) or RT-PCR (for NMIIC and MYPT-1) were performed. Additionally, immunofluorescence of primary hippocampal neurons was conducted for NMIIA, NMIIB, NMIIC, RLC and MYPT1, as detailed below. For immunoblotting, cell extracts were prepared in lysis buffer (0.3% Triton X-100 (Sigma-Aldrich, cat\# T9284-100ML), protease inhibitors (cOmplete, Mini, Roche, Merck, cat\# 04693124001) and 2 mM orthovanadate (Sigma-Aldrich, cat\# S6508-10G) in PBS), run in 10% SDS-PAGE gels and transferred to Amersham Protran Premium 0.45 μm nitrocellulose membranes (GE Healthcare Life Sciences, VWR International, cat\# GEHE10600003). The following primary antibodies were used: rabbit anti-NMIIA (Sigma-Aldrich, cat\# M8064, 1:1000), rabbit anti-NMIIB (Sigma-Aldrich, cat\# M7939, 1:1000), rabbit anti-α-adducin (Abcam, cat\# ab51130, 1:1000); rabbit anti-vinculin (Abcam cat\# ab129002, 1:1000), mouse anti-β-actin (Sigma-Aldrich, cat\# A5441, 1:5000), and mouse anti-α-tubulin (Sigma-Aldrich, cat\# T6199, 1:1000). The secondary antibodies donkey anti-rabbit IgG conjugated with horseradish peroxidase (HRP) (Jackson Immuno Research, cat\# 711-035-152, 1:5000) and donkey anti-mouse IgG conjugated with HRP (Jackson Immuno Research, cat\# 715-035-151, 1:5000) were employed. Quantifications were performed using Quantity One 1-D Analysis Software version 4.6 (Bio-Rad). In the case of RT-PCR, RNA from CAD and PC12 cells was extracted using NZY Total RNA Isolation Kit (NZY Tech, cat\# MB13402). RNA concentration and purity were determined by NanoDrop spectrophotometry, and integrity was assessed using BioRad\'s Experion RNA chip. cDNA synthesis was performed with SuperScript First-Strand Synthesis System for RT-PCR (Thermo Fisher Scientific, cat\# 11904018). RT-PCR was done using the following specific primers: for NMIIC (forward 5'-CCTGGCTGAGTTCTCCTCAC-3' and reverse 5'-TGCTTCTGCTCCATCATCTG-3', for amplification of a 207 bp fragment); for MYPT1 (forward 5'-AAGGGAACGAAGAGCTCTAGAAA-3' and reverse 5'-TGACAGTCTCCAGGGGTTCT-3', for amplification of a 242 bp fragment; β-actin (forward 5'-ACCACACCTTCTACAATGAG-3' and reverse 5'-TAGCACAGCCTGGATAGC-3', for amplification of a 161 bp fragment) and GADPH (forward 5'-AGGCACCAAGATACTTACAAAAAC-3' and reverse 5'- TGTATTGTAACCAGTCATCAGCA-3', for amplification of a 193 bp fragment).

Immunolabeling {#s3-4}
--------------

Primary hippocampal neurons were fixed with 4% PFA, in PBS at pH 7.4 for 20 min at room temperature. Fixed cells were permeabilized with 0.1% (v/v) triton X-100 (in PBS) for 5 min and autofluorescence was quenched with 0.2M ammonium chloride (Merck, cat\# 1.01145.0500). Non-specific labeling was blocked by incubation with blocking buffer (5% FBS in PBS) for 1 hr. Primary antibodies diluted in blocking buffer were incubated overnight at 4°C: mouse anti-βII-spectrin (BD Transduction, cat\# 612563, 1:200), rabbit anti-MAP2 (Synaptic Systems, cat\# 188002, 1:20000), rabbit anti-NMIIA (Sigma-Aldrich, cat\# M8064, 1:200), rabbit anti-NMIIB (Sigma-Aldrich, cat\# M7939, 1:200), rabbit anti-NMIIC (a kind gift from Dr Robert Adelstein, 1:40), rabbit anti-pMLC2 Thr18/Ser19 (Cell Signaling, cat\# 3674, 1:50), rabbit anti-MLC2 (Cell Signaling, cat\# 1678505S, 1:40), and rabbit anti-MYPT1 (Cell Signaling, cat\# 2634, 1:50). After three 5 min washes in PBS, incubation with secondary antibody was performed for 1 hr at room temperature. For STED microscopy, the following secondary antibodies were used: goat anti-mouse STAR 635P (Abberior GmbH, cat\# 2-0002-007-5, 1:200); goat anti-rabbit STAR 635P (Abberior GmbH, cat\# 2-0012-007-2, 1:200); goat anti-mouse STAR 580 (Abberior GmbH, cat\# 2-0002-005-1, 1:200) and goat anti-rabbit STAR 580 (Abberior GmbH, cat\# 2-0012-005-8, 1:200). For actin staining, 0.3 µM phalloidin 635P (Abberior GmbH, cat\# 2-0205-002-5, in PBS), was used. Phalloidin was incubated in cells for 1 hr at 37°C following the secondary antibody incubation. For SMLM dSTORM the following secondaries were used: goat-anti mouse Alexa Fluor 532 (Thermo Fischer Scientific, cat\# A-11002, 1:200) and donkey-anti rabbit Alexa Fluor 647 (Jackson ImmunoResearch, cat\# 711-605-152, 1:200). After three 5 min PBS washes, coverslips were mounted in 80% glycerol for STED microscopy; for SMLM imaging, coverslips were mounted in GLOX/MEA buffer (detailed below) in depression slides and sealed with twinsil (Picodent, cat\# 13001000) and for immunofluorescence, the coverslips were mounted in fluoroshield with DAPI (Vector Laboratories, cat\# H-1200) and sealed with nail varnish. In the case of shRNA validations, images were acquired using a Zeiss Axio ImagerZ1 widefield microscope (Carl Zeiss) equipped with oil-immersion 63x/1.4 (Plan-Apochromat) and with Differential Interference Contrast (DIC) and a TCS Leica SP8 confocal microscope (Leica Microsystems). To validate the effectiveness of shRNA-mediated downregulation of NMIIA, NMIIB, NMIIC, RLC and MYPT1, the cell body from transfected and non-transfected cells, was delineated with the segmented line tool from Fiji, and the mean fluorescence intensity was measured. To confirm that ML-7 inhibits the phosphorylation of NMII, the AIS was delineated with the segmented line from Fiji and the mean fluorescence intensity was compared in treated and non-treated cells.

STED imaging {#s3-5}
------------

STED imaging was performed on an inverted Leica TCS SP8 STED 3X (Leica Microsystems), using DIV8 hippocampal neurons, unless otherwise indicated. Hippocampal neurons were imaged, at a fixed distance of 80--100 µm from the cell body, with a HC PLAPO CS2 100x NA 1.4 STED WHITE oil immersion objective (Leica Microsystems) using confocal and STED modes. The 2D vortex STED images with lateral resolution enhancement were recorded with 20 nm pixel size in xy and dwell times of typically 600 ns. First, the STED far-red channel (Abberior STAR 635P) was recorded with 633 nm excitation using the pulsed white light laser with 80 MHz repetition rate and STED depletion was performed with a synchronized pulsed 775 nm depletion laser. The detection bandpass was set to 650 to 750 nm and the pinhole was set to 0.93AU. The following acquisition settings were applied: 16 x line averaging and detector gating on a Hybrid Detector (HyD, Leica Microsystems) of 0.3 ns to 6 ns. The second STED channel (Abberior STAR580) was recorded in line sequential mode with 561 nm excitation and 775 nm depletion using a detection window from 580 to 620 nm. All other settings remained constant. We alternatively used an Abberior Instruments 'Expert Line' gated-STED coupled to a Nikon Ti microscope with an oil-immersion 60x 1.4 NA Plan-Apo objective (Nikon, Lambda Series) and a pinhole size set at 0.8 Airy units. The system features 40 MHz modulated excitation (405, 488, 560 and 640 nm) and depletion (775 nm) lasers. The microscope's detectors are avalanche photodiode detectors (APDs) which were used to gate the detection between \~700 ps and 8ns. To analyze ring periodicity, the maximum intensity of peaks was determined and the interpeak distance was measured. To determine axon diameter, the distance between the outer points (brighter, in the focus plane) that formed the MPS was determined. Only axons unequivocally focused in the maximum wide plan were considered. Under distinct control conditions axon diameter varied, which is probably inherent to the different cultures used throughout the study. Given the use of specific controls in each experimental setting, this variation did not interfere with the interpretation of results. The tilting of actin rings was determined by measuring the angle of each actin ring regarding the axonal axis using the angle tool from Fiji. The tilting angle α was measured relative to the longitudinal axon axis. Angles larger than 90° were mirrored to the first quadrant to yield an effective angle α~eff~=90-\|90-α\|.

SMLM imaging with dSTORM/GSDIM {#s3-6}
------------------------------

For super-resolution SMLM-imaging with the Leica SR GSD using the dSTORM/GSDIM protocol, 18 mm coverslips (50000 cells/slide) were stored in PBS after fixation and immunolabelling at 4°C. The coverslips were mounted onto a single depression slide (76 mm ×26 mm) and the cavity filled with 90--100 µl GLOX-MEA buffer (0.5 mg/ml glucose oxidase (Sigma-Aldrich, cat\# [G7141](https://www.sigmaaldrich.com/catalog/product/sigma/g7141?lang=pt&region=PT), 40 μg/ml catalase (Sigma-Aldrich, cat\# [02071](https://www.sigmaaldrich.com/catalog/product/sigma/02071?lang=pt&region=PT)) 10% w/v glucose (Sigma-Aldrich, cat\# [49163](https://www.sigmaaldrich.com/catalog/product/sigma/49163?lang=pt&region=PT)), 50 mM Tris-HCl pH 8.0, 10 mM NaCl and 10 mM β-mercaptoethylamine (Sigma-Aldrich, cat\# M9768-5G)). The buffer was freshly prepared before imaging. Imaging was performed with a Leica SR GSD system using a HC PL APO 160×/NA 1.43 oil objective. The images were recorded with an Andor iXon 897 EMCCD camera at 40 Hz using a central 180 pixel x 180 pixel subregion. For excitation, a 532 nm laser (500 mW maximum power output) and a 642 nm laser (500 mW maximum power output) were used and attenuated using an AOTF when appropriate. The two fluorophores were recorded sequentially and image acquisition, single molecule analysis and image reconstruction was performed with Leica LAS X 1.9.0.13747.

Spinning disk imaging {#s3-7}
---------------------

Differentiated SH-SY5Y cells (6500 cells/well) and DIV6-hippocampal neurons (50000 cells/well) were co-transfected with CMV-eGFP-NMIIA (Addgene, cat\# 11347) and NMIIA-mApple (a kind gift from Dr John Hammer) using 1 µg:1 µg of each construct/well and Lipofectamine 3000 following the manufacturer's instructions. Two days later, in the case of SH-SY5Y cells, and four days later (at DIV10) in the case of primary hippocampal neurons, the cells were fixed. Transfected cells were then imaged using an Olympus SpinSR10 spinning disk confocal super‐resolution microscope (Olympus, Tokyo, Japan) equipped with an PlanAPON 60 ×/1.42 NA oil objective (Olympus), a CSU-W1 SoRa-Unit (Yokogawa, Tokyo, Japan) with 3.2x magnification and ORCA‐Flash 4.0 V3 Digital CMOS Camera (Hamamatsu, Hamamatsu City, Japan).

Preparation of microelectrode--microfluidic devices and electrophysiology recordings {#s3-8}
------------------------------------------------------------------------------------

Custom designed µEF devices were prepared following [@bib22]. Briefly, coated MEA chips (MultiChannel Systems MCS GmbH, Germany), with 252 recording electrodes of 30 µm in diameter and a center-to-center inter-electrode spacing of 100 µm, were combined with polydimethylsiloxane (PDMS) microfluidic chambers with an appropriate microgroove spacing for compartmentalization and monitoring of axonal activity. MEAs were coated with 0.01 mg/ml of poly-D-lysine (PDL, Corning) overnight at 37°C, and then washed with sterile water. Microfluidic devices were sterilized with 70% ethanol and were gently attached to PDL-coated MEAs, creating a µEF chamber composed of two separate compartments connected by 700 μm length ×9.6 μm height ×10 μm width microchannels. The medium reservoirs were loaded with 150 μl of 5 μg/ml laminin isolated from mouse Engelbreth-Holm-Swarm sarcoma (Sigma-Aldrich Co.) and incubated overnight at 37°C. The unbound laminin-1 was removed, and chambers were refilled with Neurobasal medium and left to equilibrate for at least 2 hr at 37°C before cell seeding. Hippocampal neurons at DIVs 11, 12 and 14 were used in the electrophysiology experiments, where either blebbistatin (3 μM), or vehicle were added. Recordings were performed using a MEA2100 recording system (MultiChannel Systems MCS GmbH, Germany). The µEF devices prepared with these MEAs had 16 microchannels with 7 electrodes positioned along each microchannel, as well as 126 electrodes dedicated to the somal compartment. For each time point, recordings were obtained at a sampling rate of 20 kHz for the characterization of the overall network activity. Then, high-temporal resolution recordings were obtained at a sampling rate of 50 kHz, for a duration of 60 or 120 s, for the calculation of the conduction velocity. Throughout the experiments, the temperature was maintained at 37°C and all recorded activity was spontaneous activity. Data analysis was carried out in MATLAB R2018a (The MathWorks Inc) using custom scripts (available in GitHub at: <https://github.com/paulodecastroaguiar/Calculate_APs_velocities_in_MEAs>; copy archived at <https://github.com/elifesciences-publications/Calculate_APs_velocities_in_MEAs>; [@bib1]) and the µSpikeHunter tool ([@bib15]). Raw signals were band-pass filtered (200--3000 Hz) and spikes were detected by a threshold set to 6 × STD of the electrode noise. Electrodes with a mean firing rate (MFR) of at least 0.1 Hz were considered active. For the propagation velocity calculations, the extracted spike times were further corrected based on the voltage waveforms. To be considered a propagating event the following requirements had to be fulfilled: detection over the entire microchannel (7 electrodes); time delay between electrode pairs lower than or equal to 1 ms (minimum propagation velocity of 0.1 m/s); isolated spike in a 3 ms time window (as to ensure spike identity in all electrodes). Propagation velocity was then calculated by dividing the first-to-last electrode distance (600 μm span) by the delay between spike times. This stringent detection method eliminated any ambiguity during bursts and excluded sequences with missing spike times on at least one electrode, which drastically reduced the size but strengthened the quality of the action potentials dataset.

Statistical analysis {#s3-9}
--------------------

All measurements were performed with the researcher blinded to the experimental condition. Data are shown as mean ± s.e.m, which the exception of propagation velocity values which are shown as median ± s.d. Statistical significance was determined by Student's t-test using Prism (GraphPad Software), with exception of actin ring measurements in hippocampal neuron cultures, where one-way ANOVA was used (GraphPad Software). Sample sizes are indicated in Figure legends and significance was defined as p\*\<0.05, p\*\*\<0.01, p\*\*\*\<0.001, p\*\*\*\*\<0.0001, ns -- not significant.
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**Acceptance summary:**

The mature axon shaft of a neuron is supported by a sub-membraneous actin-spectrin network, composed of actin rings regularly spaced by spectrin tetramers. This structure may provide mechanical support for axons, but the precise molecular composition of this sub-membraneous actin-spectrin network, and it's similarities/differences to actin filament structures of other cell-types have remained elusive. This study reports that non-muscle myosin II (NMII) localizes to actin/spectrin rings of neuronal membrane periodic skeleton, and is important for regulating the expansion and contraction of axonal diameter. Moreover, by using super-resolution microscopy approaches, the authors provide evidence that NMII heavy chains are often present along the longitudinal axonal axis, being able to crosslink adjacent rings. Together, this study provides important new information on the molecular composition and functions of the membrane periodic skeleton of axons.

**Decision letter after peer review:**

Thank you for submitting your work entitled \"The membrane periodic skeleton is an actomyosin network that regulates axonal diameter and conduction\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by a Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Pirta Hotulainen (Reviewer \#2); Dylan Tyler Burnette (Reviewer \#3).

Our decision has been reached after consultation between the reviewers. Based on these discussions and the individual reviews below, we regret to inform you that your work will not be considered further for publication in *eLife*, at least in its present form.

This manuscript reports that non-muscle myosin II (NMII) localizes to actin/spectrin rings of neuronal membrane periodic skeleton, and is important in regulating the expansion and contraction of axonal diameter. The findings presented in the manuscript are potentially of significant importance in the neurobiology field.

However, the reviewers felt that the shRNA experiments lacked the necessary controls. Moreover, the super-resolution imaging experiments aiming to uncover the localization and orientation of NMII bundles in axons were too preliminary at this stage. Thus, an extensive amount of additional work would be required to address these points. *eLife*

Reviewers, however, provide some suggestions for how to improve the manuscript. Thus, if you can address these issues by performing much better shRNA controls, as well as by significantly improving the imaging to determine the localization and orientation of NMII filaments, we would be glad to consider a new submission on this topic for publication in *eLife*. In this case, the new submission would be evaluated by the three original reviewers.

Reviewer \#1:

This manuscript reports that non-muscle myosin II (NMII) localizes to actin/spectrin rings of neuronal membrane periodic skeleton, and is important for regulating the expansion and contraction of axonal diameter. The findings presented in the manuscript are potentially of significant importance in the neurobiology field, but in my opinion the second part of the manuscript focusing on the localization and orientation of NMII molecules in axons is too preliminary for publication in its present form. Thus, significant amount of additional imaging experiments aiming to better unravel the orientation of NMII molecules in axonal membrane periodic skeleton are required to strengthen the study.

Essential revisions:

1\) While the periodic ring structure is clearly visible with BII-spectrin immunostaining (Figure 1), the periodicity is not obvious from pMLC and NMIIA/NMIIB antibody stainings presented in Figures 3 and Figure 4. Moreover, due to the bipolar nature of NMII filaments, pMLC should be visible as doublets with a spacing of 200-300 nm (see e.g. Beach et al., 2014; Fenix et al., 2016), but this is not obvious from the images presented in Figure 3. To more convincingly detect the localization of NMII in axons, the authors could perhaps consider using fluorescent NMII fusion proteins for these studies.

2\) The NMII imaging experiments would be much more informative if the authors could simultaneously visualize the myosin motor domains and rods (see e.g. Fenix et al., 2016). Such experiments would provide more information about the actual orientation of NMII molecules along the axon, and help distinguishing between the possible orientations presented in Figure 4K.

3\) In a schematic model (Figure 4K) the lengths of NMII filaments are highly variable. This does not match with the published literature, which to my knowledge suggest that the NMIIA and NMIIB bundles have regular lengths of approximately 300 nm (e.g. Billington et al., 2013). Thus, the authors should revise the model by taking into account the regular lengths of NMII filaments.

Reviewer \#2:

Costa et al. manuscript is a short but carefully done report describing the role of acto-myosin contractility in the regulation of axonal diameter. Authors have used two molecules inhibiting myosin II contractility, one drug to activate myosin II contractility and one negative control drug against myoV contractility. Drug experiments were confirmed using shRNA approach and shRNAs were also tested against many units of myosin II complex, namely: myosin heavy chain, regulatory light chain and protein dephosphorylating (inactivating) myosin light chain (knock-down results more contractile myosin II). Authors also tested which of three myosin II isoforms, A, B or C, were responsible for axonal contractility (A and B positive, C not). All these attempts show the same result, myosin II contractility causes shrinking of axons. When the contractility is released by the way or another, axon diameter increases. To me, these results look very convincing.

1\) Figure 1:

A. It is not clear what exactly the model on the right shows. If it visualizes contractility, actin filaments should slide closer to each other but here myosin II complex jumps forward.

L. and M. Myosin II manipulations did not affect periodicity of actin rings -- but how about tilting of actin rings? I am not sure if tilting can be analyzed from STED images (how \"straight\" lines (actin rings) are) but I would be curious to see the result. I hope that it gives an insight of the directionality of myosin II contractility. If myosin II contracts inside rings, there should not be any tilting, but if myosin II contracts between rings, rings might tilt (change their angle).

L and M. are labeled as describing periodicity but to be exact, the analysis measures the average distance between peaks, not periodicity.

Figure legend mentions number of axons but it is not clear how many independent experiments these axons were taken from.

2\) Figure 1---figure supplement 1: the title says: \"Modulation of NMII activity regulates both the expansion and the contraction of axonal diameter\", but the figure doesn\'t mention anything about the diameter of axons. Maybe good to change the title of the Figure.

3\) Figure 2: Authors speculate that \" One possibility is that inhibition of NMII activity might also affect the distribution of axonal sodium channels.\" This would be relatively easy to test by antibody staining of sodium channels and analysis of distribution. This experiment is optional.

4\) Figure 4:

4B is dim and blurry, any possibilities to have a better image of phalloidin + myosin IIA?

4C: Just commenting that NMIIB staining looks exactly as it looks in our laboratory. For some reason, field expects that myosin II would show nice repeating periodicity but it does not. Staining looks a bit scattered as shown here, although there is also periodicity. I think we need to accept this and start to elucidate what does it mean.

4G XZ projection and 4J: where is the cell surface and inner \"mid-point\"? Give directions.

5\) Figure 3:

I cannot see the concluded periodicity for pMLC from figures. To me it looks similar to myosin II heavy chains and my conclusion would be that pMLC and heavy chain are in complex and myosin II complex can be in different orientations. It would be interesting to have pMLC+ heavy chain together in super-resolution. Image might be complicated depending on the sites of labels but at same time, it could give an idea for the orientation of the complex. Would co-imaging of pMLC and myosin heavy chain be possible?

6\) Figure 4K: Model figure: Here are many possibilities. I would ask authors to consider the length of myosin II complexes (bipolar (=300 nm)/ unipolar) and average diameter of an axon ring (here 400 nm, enlarged to 500 nm when contractility was abolished) to get reality to models. As much as I understand, myosin II complex is not changing its length, myosin II heavy chains are not sliding along each other as shown in the model figure.

If d) is the proposed model, I would expect that in xy, myosin II staining should follow the periodicity of actin rings but it does not. To me it seems that there is definitively something between rings. Is it sure that myosin II indeed attach actin filaments in actin rings? Are there other alternative actin filament structures in axons to bind?

Reviewer \#3:

Costa et al., present evidence that myosin II contractility can regulate the diameter of neuronal axons. In addition, they provide striking super resolution imaging that support the proposed orientations of myosin II filaments in relation to the periodic actin rings along axons. This study is of potential interest. However, the authors have failed to provide controls for the vast majority of their experiments, which makes their implications difficult to interpret.

1\) The authors use hsRNA to knockdown myosin II paralogs. Maybe I somehow missed it but there does not seem to be any evidence presented that the shRNA knockdown the myosin II paralogs in hippocampal neurons. Showing that they work in other cells (i.e., PC-12 or CAD) is not sufficient to make the claim that they are knockdown in primary cultured neurons. The authors should report how much is each myosin II paralog knocked down?

2\) The authors make no attempt to show that phenotype reported for each shRNA knockdown is specifically because of the loss of the targeted paralog. The authors should reintroduce full length versions of each targeted paralog to test if it rescues the phenotype and relate the expression amount to endogenous levels in wild type axons. That is, does reintroduction lead to smaller axons?

3\) By presented the aforementioned controls for the shRNA knockdowns, the authors will add sufficient support for the use of blebbistatin. However, there is also currently no controls presented to support their claim that ML-7 is inhibiting MLCK in hippocampal neurons. Is the phosphorylation of myosin light chain reduced in the neurons (either mono or di-phosphorylation)? In addition, it would be advisable to test if the ROCK inhibitor, Y-27632, also induces wider axons.

4\) The authors claim that calyculin A is a protein phosphatase 1 (PP1) inhibitor. While this is the case, the omission that it is also a PP2A inhibitor implies a specificity that does not exist. As such, it is advisable to control for the use calyculin A. At the very least, it should be demonstrated that blebbistatin is able to mask the phenotypes induced by calyculin A.

5\) What is the evidence that myosin V is being inhibited in the neurons by Myovin-1?

6\) It does not seem to me that the singular use of blebbistatin is enough to make any claims as to the role of myosin II in regulating propagation velocity. This data seems preliminary at best.

10.7554/eLife.55471.sa2

Author response

> Reviewer \#1:
>
> This manuscript reports that non-muscle myosin II (NMII) localizes to actin/spectrin rings of neuronal membrane periodic skeleton, and is important for regulating the expansion and contraction of axonal diameter. The findings presented in the manuscript are potentially of significant importance in the neurobiology field, but in my opinion the second part of the manuscript focusing on the localization and orientation of NMII molecules in axons is too preliminary for publication in its present form. Thus, significant amount of additional imaging experiments aiming to better unravel the orientation of NMII molecules in axonal membrane periodic skeleton are required to strengthen the study.
>
> Essential revisions:
>
> 1\) While the periodic ring structure is clearly visible with BII-spectrin immunostaining (Figure 1), the periodicity is not obvious from pMLC and NMIIA/NMIIB antibody stainings presented in Figure 3 and Figure 4. Moreover, due to the bipolar nature of NMII filaments, pMLC should be visible as doublets with a spacing of 200-300 nm (see e.g. Beach et al., 2014; Fenix et al., 2016), but this is not obvious from the images presented in Figure 3. To more convincingly detect the localization of NMII in axons, the authors could perhaps consider using fluorescent NMII fusion proteins for these studies.

pMLC is expected to have a periodicity of \~190 nm if myosin is anchored to actin rings. Please note that this periodicity is still compatible with the existence of \~300 nm bipolar NMII filaments in axons (Figure 4O). A 190 nm periodic pMLC staining, coincident with phalloidin, was previously shown restricted to the AIS (Berger et al., 2018). This observation suggested that in the AIS, pMLC is bound to actin rings. Here we show that pMLC extends to the axon shaft (Figure 3D-F). Interestingly, in some axonal regions, pMLC showed a periodic distribution consistent with anchoring of myosin to different regions of consecutive actin rings (Figure 3D- highlighted by red ruler; and Figure 3F). The absence of a generalized striped pattern for pMLC (as is observed for axonal actin and βII-spectrin staining), supports that in each actin ring a limited number of pMLC molecules is anchored. Alternatively, technical limitations of the antibodies used may preclude the visualization of the entire pool of pMLC molecules present in the structure. Nonetheless, we now provide new imaging data showing that in some regions of the axon shaft, pMLC can be observed with the expected striped pattern, colocalized with actin (Figure3G). This supports that pMLC is bound to actin rings throughout the axon shaft. This issue is further discussed in the revised version of the manuscript (subsection "Phosphorylated NMII light chains are colocalized with actin within the MPS and organized as circular periodic structures persisting throughout the axon shaft")

In the case of NMII heavy chains, please note that we imaged it using antibodies that recognize the middle portion of the NMII bipolar filament (Figure 4A-D). Unless NMII heavy chains would be positioned only within individual actin rings, a periodic pattern coincident with phalloidin is not expected. As suggested by the Reviewer, hippocampal neurons and the neuroblastoma cell line SH-SY5Y were transfected with fluorescent NMII fusion constructs that allow visualizing simultaneously the N- (eGFP tag) and C-terminal (mApple tag) of NMII heavy chain (Beach et al., 2014). NMII was then visualized using spinning disk super-resolution microscopy. In the revised version of the manuscript, we show that in axons, NMIIA can assemble into bipolar filaments of \~300 nm in length (Figure 4H and 4I). Similarly, to the data obtained by STORM (Figure 4D), fluorescent NMII fusion proteins revealed the existence of multiple consecutive myosin filaments, with different orientations in relation to the axonal axis. These results are presented and discussed in subsection "NMII heavy chains have multiple orientations in relation to individual actin rings and to the axonal axis, being able to crosslink adjacent rings".

> 2\) The NMII imaging experiments would be much more informative if the authors could simultaneously visualize the myosin motor domains and rods (see e.g. Fenix et al., 2016). Such experiments would provide more information about the actual orientation of NMII molecules along the axon, and help distinguishing between the possible orientations presented in Figure 4K.

As suggested by the reviewer and detailed above, we have imaged axonal myosin after transfection with fluorescent NMII fusion constructs (Figure 4 H and 4I). Our data shows the existence of bipolar NMII filaments of \~300 nm in length positioned along the axonal axis (supporting our previous STORM analysis of the NMII heavy chain- Figure 4D). Although the simultaneous observation of the two NMII fluorophores and either actin or βII-spectrin staining was technically not possible to implement, this new data demonstrates that multiple consecutive myosin filaments are positioned along the axonal axis.

> 3\) In a schematic model (Figure 4K) the lengths of NMII filaments are highly variable. This does not match with the published literature, which to my knowledge suggest that the NMIIA and NMIIB bundles have regular lengths of approximately 300 nm (e.g. Billington et al., 2013). Thus, the authors should revise the model by taking into account the regular lengths of NMII filaments.

As requested by the reviewer, the models have been revised to accommodate the regular maximum lengths of approximately 300 nm of NMII filaments as well as an average axonal diameter of 450 nm.

> Reviewer \#2:
>
> Costa et al. manuscript is a short but carefully done report describing the role of acto-myosin contractility in the regulation of axonal diameter. Authors have used two molecules inhibiting myosin II contractility, one drug to activate myosin II contractility and one negative control drug against myoV contractility. Drug experiments were confirmed using shRNA approach and shRNAs were also tested against many units of myosin II complex, namely: myosin heavy chain, regulatory light chain and protein dephosphorylating (inactivating) myosin light chain (knock-down results more contractile myosin II). Authors also tested which of three myosin II isoforms, A, B or C, were responsible for axonal contractility (A and B positive, C not). All these attempts show the same result, myosin II contractility causes shrinking of axons. When the contractility is released by the way or another, axon diameter increases. To me, these results look very convincing.
>
> 1\) Figure 1:
>
> A. It is not clear what exactly the model on the right shows. If it visualizes contractility, actin filaments should slide closer to each other but here myosin II complex jumps forward.

As pointed out by the reviewer, to represent contractility, actin filaments have placed closer to each other.

> L. and M. Myosin II manipulations did not affect periodicity of actin rings -- but how about tilting of actin rings? I am not sure if tilting can be analyzed from STED images (how \"straight\" lines (actin rings) are) but I would be curious to see the result. I hope that it gives an insight of the directionality of myosin II contractility. If myosin II contracts inside rings, there should not be any tilting, but if myosin II contracts between rings, rings might tilt (change their angle).

As suggested by the reviewer, the possible tilting of actin rings has been measured for all drug treatments and Sh downregulations (Figure 1L and M of the revised version of the manuscript). A tilting angle D was measured relative to the longitudinal axon axis. Angles larger than 90º were mirrored to the first quadrant to yield an effective angle D~eff~ 90-\|90-D\_ In the absence of this correction, the average value would always artificially tend to 90 degrees. No variations were found, suggesting that myosin II probably does not contract between adjacent rings. However, it is also possible that adjacent actin rings may not tilt given the βII-spectrin scaffold. We also highlight that it is possible that having several active NMII filaments attached to the adjacent axon rings, the generated net force would be averaged out and thus close to zero. This has been added to subsection "Modulation of NMII activity regulates the expansion and contraction of axonal diameter".

> L and M. are labeled as describing periodicity but to be exact, the analysis measures the average distance between peaks, not periodicity.

As suggested, in the y axis of the graphs Figure 1L and M (now Figure 1N and O), "Periodicity" has been replaced by "Average distance between peaks".

> Figure legend mentions number of axons but it is not clear how many independent experiments these axons were taken from.

In every experiment displayed, at least 3 independent experiments have been performed. This is now stated in the figure legend.

> 2\) Figure 1---figure supplement 1: the title says: \"Modulation of NMII activity regulates both the expansion and the contraction of axonal diameter\", but the figure doesn\'t mention anything about the diameter of axons. Maybe good to change the title of the Figure.

The title of Figure 1---figure supplement 1 has been changed to: "Analysis of ML-7 activity and ShRNA-mediated downregulation."

> 3\) Figure 2: Authors speculate that \" One possibility is that inhibition of NMII activity might also affect the distribution of axonal sodium channels.\" This would be relatively easy to test by antibody staining of sodium channels and analysis of distribution. This experiment is optional.

Given the optional character of this experiment, this has not been included. However, this issue is discussed in subsection "Propagation velocity is altered by manipulation of NMII activity".

> 4\) Figure 4:
>
> 4B is dim and blurry, any possibilities to have a better image of phalloidin + myosin IIA?

Figure 4B has been changed and an image of better quality is now provided.

> 4C: Just commenting that NMIIB staining looks exactly as it looks in our laboratory. For some reason, field expects that myosin II would show nice repeating periodicity but it does not. Staining looks a bit scattered as shown here, although there is also periodicity. I think we need to accept this and start to elucidate what does it mean.

We were very pleased to know that similar observations on NMIIB staining were obtained independently.

> 4G XZ projection and 4J: where is the cell surface and inner \"mid-point\"? Give directions.

The cell surface and inner mid-point are now indicated in the figure.

> 5\) Figure 3:
>
> I cannot see the concluded periodicity for pMLC from figures. To me it looks similar to myosin II heavy chains and my conclusion would be that pMLC and heavy chain are in complex and myosin II complex can be in different orientations. It would be interesting to have pMLC+ heavy chain together in super-resolution. Image might be complicated depending on the sites of labels but at same time, it could give an idea for the orientation of the complex. Would co-imaging of pMLC and myosin heavy chain be possible?

We agree with the reviewer that our data supports that pMLC and NMII can be in complex in axons and that the myosin II complex can be in different orientations. This has been reinforced in the revised version of the manuscript (Subsection "Structural organization and dynamics of actomyosin axonal rings"). Although co-imaging of pMLC and myosin heavy chain was not possible to implement given host antibody constraints, we used an alternative approach to visualize the N- and C-terminus of NMII heavy chains suggested by reviewer 1 (detailed below). Of note, reviewer\#1 raised similar concerns. We are transcribing the answer provided:

pMLC is expected to have a periodicity of \~190 nm if myosin is anchored to actin rings. Please note that this periodicity is still compatible with the existence of \~300 nm bipolar NMII filaments in axons (Figure 4O). A 190 nm periodic pMLC staining, coincident with phalloidin, was previously shown restricted to the AIS (Berger et al., 2018). This observation suggested that in the AIS, pMLC is bound to actin rings. Here we show that pMLC periodicity extends to the axon shaft (Figure 3D-F). Interestingly, in some axonal regions, pMLC showed a periodic distribution consistent with anchoring of myosin to different regions of consecutive actin rings (Figure 3D- highlighted by red ruler; and Figure 3F). The absence of a generalized striped pattern for pMLC (as is observed for axonal actin and βII-spectrin staining), supports that in each actin ring a limited number of pMLC molecules is anchored. Alternatively, technical limitations of the antibodies used may preclude the visualization of the entire pool of pMLC molecules present in the structure. Nonetheless, we now provide new imaging data showing that in some regions of the axon shaft, pMLC can be observed with the expected striped pattern, colocalized with actin (Figure 3G). This supports that pMLC is bound to actin rings throughout the axon shaft. This issue is further discussed in the revised version of the manuscript (subsection "Phosphorylated NMII light chains are colocalized with actin within the MPS and organized as circular periodic structures persisting throughout the axon shaft").

In the case of NMII heavy chains, please note that we imaged it using antibodies that recognize the middle portion of the NMII bipolar filament (Figure 4A-D). Unless NMII heavy chains would be positioned only within individual actin rings, a periodic pattern coincident with phalloidin is not expected. As suggested by the Reviewer, hippocampal neurons and the neuroblastoma cell line SH-SY5Y were transfected with fluorescent NMII fusion constructs that allow visualizing simultaneously the N- (eGFP tag) and C-terminal (mApple tag) of NMII heavy chain (Beach et al., 2014). NMII was then visualized using spinning disk super-resolution microscopy. In the revised version of the manuscript, we show that in axons, NMIIA can assemble into bipolar filaments of \~300 nm in length (Figure 4H and 4I). Similarly, to the data obtained by STORM (Figure 4D), fluorescent NMII fusion proteins revealed the existence of multiple consecutive myosin filaments, with different orientations in relation to the axonal axis. These results are presented and discussed in subsection "NMII heavy chains have multiple orientations in relation to individual actin rings and to the axonal axis, being able to crosslink adjacent rings".

> 6\) Figure 4K: Model figure: Here are many possibilities. I would ask authors to consider the length of myosin II complexes (bipolar (=300 nm)/ unipolar) and average diameter of an axon ring (here 400 nm, enlarged to 500 nm when contractility was abolished) to get reality to models. As much as I understand, myosin II complex is not changing its length, myosin II heavy chains are not sliding along each other as shown in the model figure.

As requested by the reviewer, the models have been revised to accommodate the regular maximum lengths of approximately 300 nm of NMII filaments, as well as an average axonal diameter of 450 nm.

> If d) is the proposed model, I would expect that in xy, myosin II staining should follow the periodicity of actin rings but it does not. To me it seems that there is definitively something between rings. Is it sure that myosin II indeed attach actin filaments in actin rings? Are there other alternative actin filament structures in axons to bind?

This aspect is further discussed in the revised version of the manuscript (subsection "Structural organization and dynamics of actomyosin axonal rings"). The presence of NMII staining that is non-coincident with actin, supports that NMII heavy chains may crosslink different rings. Periodic (\~190 nm) pMLC staining, coincident with phalloidin staining restricted to the AIS has been previously shown using STORM (Berger et al., 2018. Thus, binding of pMLC to actin has been hypothesized. Here, as detailed above and further documented in the manuscript, we show that an approximately 190 nm periodicity of pMLC is maintained throughout the axon shaft (Figure 3D-G). Despite this evidence and the fact that NMII activity modulates MPS diameter, the possible interplay between myosinII and deep axonal actin filaments that may also serve as myosin anchors, cannot be ruled out and should certainly be explored in the future. This is further discussed in the revised version of the manuscript (subsection "Structural organization and dynamics of actomyosin axonal rings").

> Reviewer \#3:
>
> Costa et al. present evidence that myosin II contractility can regulate the diameter of neuronal axons. In addition, they provide striking super resolution imaging that support the proposed orientations of myosin II filaments in relation to the periodic actin rings along axons. This study is of potential interest. However, the authors have failed to provide controls for the vast majority of their experiments, which makes their implications difficult to interpret.
>
> 1\) The authors use hsRNA to knockdown myosin II paralogs. Maybe I somehow missed it but there does not seem to be any evidence presented that the shRNA knockdown the myosin II paralogs in hippocampal neurons. Showing that they work in other cells (i.e., PC-12 or CAD) is not sufficient to make the claim that they are knockdown in primary cultured neurons. The authors should report how much is each myosin II paralog knocked down?

Assays on the efficacy of myosin-II knock-down have been performed in cell lines as the transfection efficiency of hippocampal neurons is very low precluding western blot or qPCR analysis of transfected cells. To address the concern raised by the reviewer, in the revised version of the manuscript we have added to Figure 1---figure supplement 1 the quantification of the efficacy of each shRNA-mediated knockdown in hippocampal neurons, as assessed by quantification of immunofluorescence intensities.

> 2\) The authors make no attempt to show that phenotype reported for each shRNA knockdown is specifically because of the loss of the targeted paralog. The authors should reintroduce full length versions of each targeted paralog to test if it rescues the phenotype and relate the expression amount to endogenous levels in wild type axons. That is, does reintroduction lead to smaller axons?

As suggested by the reviewer, for each of the shRNA experiments, full length shRNA resistant constructs have been used to show rescue. In each case, the use of shRNA resistant constructs led to reversion of phenotypes (Figure 1J,K; subsection "Modulation of NMII activity regulates the expansion and contraction of axonal diameter").

> 3\) By presented the aforementioned controls for the shRNA knockdowns, the authors will add sufficient support for the use of blebbistatin. However, there is also currently no controls presented to support their claim that ML-7 is inhibiting MLCK in hippocampal neurons. Is the phosphorylation of myosin light chain reduced in the neurons (either mono or di-phosphorylation)? In addition, it would be advisable to test if the ROCK inhibitor, Y-27632, also induces wider axons.

As requested by the reviewer, in the revised version of the manuscript we show using immunofluorescence against pMLC that ML-7 inhibits MLCK in hippocampal neurons (Figure 1---figure supplement 1A and B, subsection "Modulation of NMII activity regulates the expansion and contraction of axonal diameter").

> 4\) The authors claim that calyculin A is a protein phosphatase 1 (PP1) inhibitor. While this is the case, the omission that it is also a PP2A inhibitor implies a specificity that does not exist. As such, it is advisable to control for the use calyculin A. At the very least, it should be demonstrated that blebbistatin is able to mask the phenotypes induced by calyculin A.

As suggested by the reviewer, we now show that blebbistatin reverts the phenotype induced by calyculin A (Figure 1D,E; subsection "Modulation of NMII activity regulates the expansion and contraction of axonal diameter").

> 5\) What is the evidence that myosin V is being inhibited in the neurons by Myovin-1?

Myovin-1 specifically arrests the myosinV ATP/ADP cycle, thus inhibiting myosin V as a processive motor (Islam et al., 2010). Recent studies have further used myovin-1 in hippocampal neurons to inhibit myosinV-dependent intersynaptic vesicle exchange in live cells (Gramlich et al., 2017). This has been further clarified in the text, subsection "Modulation of NMII activity regulates the expansion and contraction of axonal diameter".

> 6\) It does not seem to me that the singular use of blebbistatin is enough to make any claims as to the role of myosin II in regulating propagation velocity. This data seems preliminary at best.

In the current version of the manuscript, we further explored the effect of blebbistatin in the regulation of propagation velocity, by increasing the number of analyses performed and by measuring the mean firing rate (MFR) in both blebbistatin-treated and untreated neurons. Also, the need to further explore this effect through the use of additional modulators of NMII activity and shRNA-mediated downregulation approaches, is now discussed (subsection "Propagation velocity is altered by manipulation of NMII activity").
